SOLACI-CACI 2021 | DAPT Session

✔️ Watch again the DAPT Session in the SOLACI-CACI 2021 Congress.

👨‍🏫 Program:

  • 02:58 – Short versus long-term DAPT Therapy in High Risk Bleeding. Rationality and Preliminary Results of Master DAPT trial – Peter Smits.
  • 31:20 – Rationality of long-term DAPT in Chronic Stable Angina – Ernesto Duronto.
  • 48:14 – Selection of the best P2Y12 in Patients with ACS and STEMI: Evidence from Registries – Alfredo E. Rodríguez. 58:55 – Current Indication of Ticagrelor – Roxana Merhan.
  • 01:07:25 – Prasugrel or Ticagrelor in Acute Coronary Syndromes: the ISAR-REACT Trial – Adnan Kastrati.

👉🏻 Panelists: Curotto, Valeria – Iglesias, Ricardo – Piraino, Rubén – Pocoví , Antonio – Salvatori, Carolina – Santaera, Omar – Sztutzbach, Pablo G.
👉🏻 Chairpersons: José Mangione & Fausto Feres


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...